Key result
Prostaglandin E2, via the EP2 receptor and cAMP elevation, specifically downregulates PAR-1 mRNA and protein levels in human lung fibroblasts through protein kinase A activity.
Why the study?
Does prostaglandin E2 downregulate PAR-1 expression in human lung fibroblasts?
Does prostaglandin E2 downregulate PAR-1 expression in human lung fibroblasts?
PGE2 specifically downregulates PAR-1 expression in human lung fibroblasts via the EP2 receptor and PKA pathway, suggesting a therapeutic mechanism for controlling fibroblast function in fibrotic diseases.
Answers are grounded in this paper and cite their sources.
May modulate fibroblast activity in pulmonary fibrosis via EP2-PKA; hypothesis-generating for targeted therapies pending clinical validation.
Many cellular functions of lung fibroblasts are controlled by protease-activated receptors (PARs). In fibrotic diseases, PAR-1 plays a major role in controlling fibroproliferative and inflammatory responses. Therefore, in these diseases, regulation of PAR-1 expression plays an important role. Using the selective prostaglandin EP2 receptor agonist butaprost and cAMP-elevating agents, we show here that prostaglandin (PG)E(2), via the prostanoid receptor EP2 and subsequent cAMP elevation, downregulates mRNA and protein levels of PAR-1 in human lung fibroblasts. Under these conditions, the functional response of PAR-1 in fibroblasts is reduced. These effects are specific for PGE(2). Activation of other receptors coupled to cAMP elevation, such as beta-adrenergic and adenosine receptors, does not reproduce the effects of PGE(2). PGE(2)-mediated downregulation of PAR-1 depends mainly on protein kinase A activity, but does not depend on another cAMP effector, the exchange protein activated by cAMP. PGE(2)-induced reduction of PAR-1 level is not due to a decrease of PAR-1 mRNA stability, but rather to transcriptional regulation. The present results provide further insights into the therapeutic potential of PGE(2) to specifically control fibroblast function in fibrotic diseases.
No takes yet. Share an insight, caveat, or question.
Sokolova et al. (2008) studied Fibrotic diseases. Prostaglandin E2 (PGE2) was evaluated on PAR-1 mRNA and protein levels. Prostaglandin E2, via the EP2 receptor and cAMP elevation, specifically downregulates PAR-1 mRNA and protein levels in human lung fibroblasts through protein kinase A activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: